SEATTLE, January 15, 2008 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced that the company has been granted a broad European patent covering the company's lead product candidate Provenge(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. European patent No. 0 870 022 B1 covers the composition of matter of PROVENGE as well as the company's other active cellular immunotherapy (ACI) product candidates, such as NEUVENGE(TM) (lapuleucel-T), which utilize Dendreon's Antigen Delivery Cassette(TM) technology. The patent also covers methods of activating antigen presenting cells in vitro with certain fusion proteins developed by Dendreon, including the fusion protein that is used in PROVENGE.
"The approval of this broad patent covering PROVENGE and our other active cellular immunotherapies in Europe is an important milestone for the company," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "While our priority is to obtain the approval of PROVENGE in the United States, the issuance of this key patent solidifies the commercial potential of PROVENGE and our ACI platform on a more international basis. Prostate cancer is a global unmet need with, according to Cancer Research UK, approximately 670,000 men diagnosed with the disease each year, and we believe that PROVENGE could have a worldwide impact on the treatment of prostate cancer."
No comments:
Post a Comment